Publications by authors named "Michael P Gulseth"

Claim this Profile
C
Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
Scott J Dingus, Alex R Smith, William E Dager, Sara Zochert, Salli A Nothdurft, Michael P Gulseth

Ann Pharmacother· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
Alex R Smith, William E Dager, Michael P Gulseth

Am J Health Syst Pharm· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
Colin G Kaide, Michael P Gulseth

J Emerg Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Direct Oral Anticoagulants in Morbidly Obese Patients.
Kazuhiko Kido, James C Lee, Thaddaus Hellwig, Michael P Gulseth

Pharmacotherapy· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Sara Zochert, Kiara M Oltman, Brittany M Elgersma, Thaddaus R Hellwig, Michael P Gulseth

Am J Health Syst Pharm· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran.
Mackenzie Byron, Sara Zochert, Thaddaus Hellwig, Marioara Gavozdea-Barna, Michael P Gulseth

Am J Health Syst Pharm· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin K antagonists, direct oral anticoagulants, and the rationale for reversal agents.
Michael P Gulseth

Am J Health Syst Pharm· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of direct oral anticoagulant therapy reversal.
Michael P Gulseth

Am J Health Syst Pharm· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between time spent at extreme International Normalized Ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients.
Ashley L Barta, Edith A Nutescu, Paul A Thompson, Henry I Bussey, Michael P Gulseth

Am J Health Syst Pharm· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban: practical considerations for ensuring safety and efficacy.
Maureen A Smythe, John Fanikos, Michael P Gulseth, Ann K Wittkowsky, Sarah A Spinler

Pharmacotherapy· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations.
Thaddaus R Hellwig, Gregory J Peitz, Michael P Gulseth

Am J Health Syst Pharm· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inpatient warfarin: experience with a pharmacist-led anticoagulation management service in a tertiary care medical center.
Sara Fowler, Michael P Gulseth, Colleen Renier, James Tomsche

Am J Health Syst Pharm· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Michael P Gulseth, Ann K Wittkowsky, John Fanikos, Sarah A Spinler, William E Dager

Pharmacotherapy· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dosing guidelines, not protocols, for managing warfarin therapy.
Ann K Wittkowsky, Sarah A Spinler, William Dager, Michael P Gulseth, Edith A Nutescu

Am J Health Syst Pharm· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of requiring a baseline International Normalized Ratio for inpatients treated with warfarin.
Rhonda J Hammerquist, Michael P Gulseth, David W Stewart

Am J Health Syst Pharm· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key articles and guidelines in the treatment of venous thromboembolism.
Paul P Dobesh, Ann K Wittkowsky, Zachary Stacy, William E Dager, Toby C Trujillo, Michael P Gulseth

Pharmacotherapy· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
Michael P Gulseth, Gloria R Grice, William E Dager

Am J Health Syst Pharm· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban: an oral direct inhibitor of factor Xa.
Michael P Gulseth, Jessica Michaud, Edith A Nutescu

Am J Health Syst Pharm· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementing anticoagulation management by pharmacists in the inpatient setting.
William E Dager, Michael P Gulseth

Am J Health Syst Pharm· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partnerships between colleges of pharmacy and small-to medium-sized hospitals.
Michael P Gulseth, Timothy P Stratton, Jennifer L Brandenburg, Debra C Sisson, Stephen G Hoag

Am J Health Syst Pharm· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer program to assist pharmacy management of an inpatient warfarin dosing service.
Brandi L Schneider, Michael P Gulseth, Michael A Cusick, Debra C Sisson, James J Tomsche

Am J Health Syst Pharm· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Ximelagatran: an orally active direct thrombin inhibitor.
Michael P Gulseth

Am J Health Syst Pharm· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing the safety of analgesia use in a community hospital.
Michael P Gulseth, Steven Meisel, Mary Meisel

Am J Health Syst Pharm· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis